CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

Corporate Breaking News

Home : CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

Aug 31 2019	CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma
SHANGHAI, Aug. 30, 2019 /PRNewswire/ -- CARsgen Therapeutics Inc., a clinical-stage biopharmaceutical company today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to its investigational CAR-T cell therapy fully human anti-BCMA (B Cell...


Source:https://www.prnewswire.com:443/news-releases/carsgen-therapeutics-receives-us-fda-orphan-drug-designation-for-fully-human-anti-bcma-b-cell-maturation-antigen-autologous-chimeric-antigen-receptor-car-t-cells-for-the-treatment-of-multiple-myeloma-300910042.

Related News
» Ping An Property Insurance to Attend WAIC 2019 with its Latest AI Innovations, Accelerating Industry Transformation » CAPITAL ONE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Capital One Financial Corporation - COF